To determine whether FMD potentiates the efficacy of immunotherapy in low immunogenic tumors such as melanoma, we tested FMD cycles lasting 4 days in combination with immunotherapy directed against the immune checkpoints PD-1 and CTLA4, successfully used in the clinic for the treatment of patients with melanoma. Here, PDCD1 is linked to melanoma.